Lung cancer immunotherapy trial halted after just 6 patients
NCT ID NCT04638582
First seen May 02, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study tested whether giving the immunotherapy drug pembrolizumab (Keytruda) before surgery, alone or with chemotherapy, helps shrink early-stage non-small cell lung cancer. Only 6 people enrolled before the trial was stopped early. The main goal was to see if the treatment could clear cancer DNA from the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
McGill University Health Center
Montreal, Quebec, H4A3J1, Canada
Conditions
Explore the condition pages connected to this study.